RX — Biosyent Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedSmall CapNeutral
- CA$88.69m
- CA$62.35m
- CA$28.62m
- 99
- 56
- 49
- 77
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.76 | ||
| PEG Ratio (f) | 0.83 | ||
| EPS Growth (f) | 19.8% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.69 | ||
| Price to Tang. Book | 2.77 | ||
| Price to Free Cashflow | 19.28 | ||
| Price to Sales | 3.2 | ||
| EV to EBITDA | 7.48 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.06% | ||
| Return on Equity | 19.38% | ||
| Operating Margin | 28.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 20.76 | 21.53 | 21.42 | 22.33 | 28.62 | 27.4 | 29.8 | 9.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +21.09 | +10.05 | -9.12 | -19.44 | +68.37 | -11.89 | +23.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioSyent Inc. is a Canada-based pharmaceutical company. The Company is focused on in-licensing or acquiring pharmaceutical and other healthcare products. It owns a legacy business that manufactures and markets Protect-It, a bio-friendly non-toxic product used in agriculture, which is operated by its subsidiary Hedley Technologies Ltd. It is a non-chemical, food-safe grain insecticide, which is used as a preventative treatment against insect infestations in stored grains and is marketed in Canada and the United States. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Powder 15, Proktis-M, RepaGyn, and cTIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell is designed for ease of use and with patient comfort and safety in mind. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
Directors
- Rene Goehrum CHM
- Robert March CFO
- Joost van der Mark VPR
- Kevin Wilson VPR
- Peter Lockhard LED
- Navid Ashrafi DRC
- Sharan Raghubir DRC
- Larry Andrews IND
- Joseph Arcuri IND
- Sara Elford IND (51)
- Stephen Wilton IND
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- May 19th, 1999
- Public Since
- May 22nd, 1981
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 12,370,161
- Address
- 2476 Argentia Road, Suite 402, MISSISSAUGA, L5N 6M1
- Web
- http://www.biosyent.com
- Phone
- +1 9052060013
- Auditors
- MNP LLP
Upcoming Events for RX
Biosyent Inc Annual Shareholders Meeting
Q1 2023 Biosyent Inc Earnings Release
Similar to RX
Acasti Pharma
TSX Venture Exchange
Aequus Pharmaceuticals
TSX Venture Exchange
Avricore Health
TSX Venture Exchange
Cannara Biotech
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
What is the Biosyent share price?
As of Today at 18:03 UTC, shares in Biosyent are trading at CA$7.17. This share price information is delayed by 15 minutes.
How has the Biosyent share price performed this year?
Shares in Biosyent last closed at CA$7.17 and the price had moved by -14.13% over the past 365 days. In terms of relative price strength the Biosyent share price has underperformed the Toronto Stock Exchange 300 Composite Index by -10.19% over the past year.
What are the analyst and broker recommendations for Biosyent?
The overall consensus recommendation for Biosyent is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biosyent dividend yield?
Biosyent does not currently pay a dividend.
Does Biosyent pay a dividend?
Biosyent does not currently pay a dividend.
When does Biosyent next pay dividends?
Biosyent does not currently pay a dividend.
How do I buy Biosyent shares?
To buy shares in Biosyent you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biosyent?
As of the previous close price of CA$7.17, shares in Biosyent had a market capitalisation of CA$88.69m.
Where are Biosyent shares listed?
Here are the trading details for Biosyent:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: RX
What kind of share is Biosyent?
Based on an overall assessment of its quality, value and momentum Biosyent is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biosyent share price forecast for 2022?
The analyst consensus target price for shares in Biosyent is CA$10.00. That is 39.47% above the last closing price of CA$7.17.
Analysts covering Biosyent currently have a consensus Earnings Per Share (EPS) forecast of CA$0.43 for the next financial year.
What is the trend in the Biosyent share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosyent. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -7.82%.
As of the last closing price of CA$7.17, shares in Biosyent were trading -11.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biosyent PE Ratio?
The Biosyent PE ratio based on its reported earnings over the past 12 months is 13.76. The shares last closed at CA$7.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biosyent?
Biosyent's management team is headed by:
- Rene Goehrum - CHM
- Robert March - CFO
- Joost van der Mark - VPR
- Kevin Wilson - VPR
- Peter Lockhard - LED
- Navid Ashrafi - DRC
- Sharan Raghubir - DRC
- Larry Andrews - IND
- Joseph Arcuri - IND
- Sara Elford - IND
- Stephen Wilton - IND